{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T08:57:07Z","timestamp":1784883427290,"version":"3.55.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3410,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,5]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>Although there have been significant advances in understanding the clinical and biochemical features of primary biliary cirrhosis (PBC), there is still a paucity of data on the usefulness of biomarkers as prognostic indicators. This is particularly important at the time of initial diagnosis. Indeed, the widespread use of antimitochondrial antibody testing has led to an earlier diagnosis of asymptomatic PBC and it is difficult to predict which patients will experience a benign versus a rapidly progressive course. To address this issue, we examined a unique population of 127 newly diagnosed patients with PBC during a 15-year period of observation that began in January 1990. Sera from these patients were analyzed for antimitochondrial, antinuclear, and anti\u2013smooth muscle antibodies, and immunoblotting was performed for nuclear pore complex (NPC). The patients were then followed up longitudinally using biochemical liver function tests. No patient was under any medical therapy for PBC at the time of the initial sera collection. Data were analyzed based not only on the clinical features, but also the Mayo score and specific outcome measures, including time to death, need for liver transplantation, and complication free survival. Among patients with early disease, bilirubin increased to &gt;2 mg\/dL in the anti-NPC(+) patients (26% vs. 5%,<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= .019). Anti-NPC antibodies remained stable or slightly increased over the period of observation.<\/jats:bold>\n                                 <jats:bold>\n                                    In conclusion\n                                 <\/jats:bold>\n                                 <jats:bold>, anti-NPC identifies patients likely to experience an unfavorable clinical course and more rapid disease progression. (Hepatology 2006;43:1135\u20131144.)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.21172","type":"journal-article","created":{"date-parts":[[2006,4,20]],"date-time":"2006-04-20T18:52:36Z","timestamp":1145559156000},"page":"1135-1144","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":156,"title":["Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis"],"prefix":"10.1097","volume":"43","author":[{"given":"J\u00f3zefa","family":"Wesierska-Gadek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Penner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Maria","family":"Battezzati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Selmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Zuin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hitchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard J.","family":"Worman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Gershwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Podda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Invernizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-31-20241201","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra043898","article-title":"Primary biliary cirrhosis.","volume":"353","author":"Kaplan","year":"2005","journal-title":"N Engl J Med"},{"key":"R2-31-20241201","first-page":"126","article-title":"Primary biliary cirrhosis: prediction of shortterm survival based on repeated patient visits.","volume":"20","author":"Murtaugh","year":"1994","journal-title":"HEPATOLOGY"},{"key":"R3-31-20241201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.1840100102","article-title":"Prognosis in primary biliary cirrhosis: model for decision making.","volume":"10","author":"Dickson","year":"1989","journal-title":"HEPATOLOGY"},{"key":"R4-31-20241201","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/gut.20.2.137","article-title":"Serum bilirubin: a prognostic factor in primary biliary cirrhosis.","volume":"20","author":"Shapiro","year":"1979","journal-title":"Gut"},{"key":"R5-31-20241201","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.4049\/jimmunol.138.10.3525","article-title":"Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis.","volume":"138","author":"Gershwin","year":"1987","journal-title":"J Immunol"},{"key":"R6-31-20241201","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/jhep.2001.26514","article-title":"Detection of antimitochondrial autoantibodies in immunofluorescent AMAnegative patients with primary biliary cirrhosis using recombinant autoantigens.","volume":"34","author":"Miyakawa","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R7-31-20241201","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1572-0241.1999.00770.x","article-title":"Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis.","volume":"94","author":"Springer","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"R8-31-20241201","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(03)13808-1","article-title":"Primary biliary cirrhosis.","volume":"362","author":"Talwalkar","year":"2003","journal-title":"Lancet"},{"key":"R9-31-20241201","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1572-0241.2002.05620.x","article-title":"Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis?","volume":"97","author":"Joshi","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R10-31-20241201","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/hep.510250507","article-title":"Comparison of the clinical features and clinical course of antimitochondrial antibodypositive and negative primary biliary cirrhosis.","volume":"25","author":"Invernizzi","year":"1997","journal-title":"HEPATOLOGY"},{"key":"R11-31-20241201","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0168-8278(02)00322-7","article-title":"Antimitochondrial antibodies in primary biliary cirrhosis.","volume":"37","author":"Neuberger","year":"2002","journal-title":"J Hepatol"},{"key":"R12-31-20241201","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0016-5085(90)91246-3","article-title":"Antinuclear antibodies directed to a 200kilodalton polypeptide of the nuclear envelope in primary biliary cirrhosis. A clinical and immunological study of a series of 150 patients with primary biliary cirrhosis.","volume":"99","author":"Lassoued","year":"1990","journal-title":"Gastroenterology"},{"key":"R13-31-20241201","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0016-5085(94)95333-3","article-title":"Autoantibodies against integral membrane proteins of the nuclear envelope in patients with primary biliary cirrhosis.","volume":"106","author":"Nickowitz","year":"1994","journal-title":"Gastroenterology"},{"key":"R14-31-20241201","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0168-8278(00)00040-4","article-title":"Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis.","volume":"34","author":"Invernizzi","year":"2001","journal-title":"J Hepatol"},{"key":"R15-31-20241201","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1542-3565(04)00465-3","article-title":"Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?","volume":"2","author":"Yang","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R16-31-20241201","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jhep.2004.11.016","article-title":"Antibody titer to gp210C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis.","volume":"42","author":"Nakamura","year":"2005","journal-title":"J Hepatol"},{"key":"R17-31-20241201","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/gut.2003.036558","article-title":"Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis.","volume":"54","author":"Rigopoulou","year":"2005","journal-title":"Gut"},{"key":"R18-31-20241201","first-page":"1123","article-title":"Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis.","volume":"26","author":"Zuchner","year":"1997","journal-title":"HEPATOLOGY"},{"key":"R19-31-20241201","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1440-1746.1998.01553.x","article-title":"Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis.","volume":"13","author":"Itoh","year":"1998","journal-title":"J Gastroenterol Hepatol"},{"key":"R20-31-20241201","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0896-8411(03)00033-7","article-title":"Profile and clinical significance of antinuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study.","volume":"20","author":"Miyachi","year":"2003","journal-title":"J Autoimmun"},{"key":"R21-31-20241201","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1572-0241.2003.07257.x","article-title":"Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis.","volume":"98","author":"Muratori","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R22-31-20241201","first-page":"477","article-title":"The cytoplasmic dot staining pattern is detected in a subgroup of patients with primary biliary cirrhosis.","volume":"32","author":"Bloch","year":"2005","journal-title":"J Rheumatol"},{"key":"R23-31-20241201","first-page":"1488","article-title":"Clinical and serological heterogeneity in patients with anticentromere antibodies.","volume":"32","author":"Miyawaki","year":"2005","journal-title":"J Rheumatol"},{"key":"R24-31-20241201","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/0891693021000064272","article-title":"The hepatiticcholestatic overlap syndrome: an Italian experience.","volume":"35","author":"Muratori","year":"2002","journal-title":"Autoimmunity"},{"key":"R25-31-20241201","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00432479","article-title":"Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis).","volume":"379","author":"Ludwig","year":"1978","journal-title":"Virchows Arch A Pathol Anat Histol"},{"key":"R26-31-20241201","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1084\/jem.182.4.1159","article-title":"Autoantibodies from patients with primary biliary cirrhosis preferentially react with the aminoterminal domain of nuclear pore complex glycoprotein gp210.","volume":"182","author":"WesierskaGadek","year":"1995","journal-title":"J Exp Med"},{"key":"R27-31-20241201","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood.V79.4.1081.bloodjournal7941081","article-title":"Nucleolar proteins B23 and C23 as target antigens in chronic graftversushost disease.","volume":"79","author":"WesierskaGadek","year":"1992","journal-title":"Blood"},{"key":"R28-31-20241201","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1083\/jcb.70.3.581","article-title":"A modified procedure for the isolation of a pore complexlamina fraction from rat liver nuclei.","volume":"70","author":"Dwyer","year":"1976","journal-title":"J Cell Biol"},{"key":"R29-31-20241201","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1053\/gast.1996.v110.pm8608894","article-title":"Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis.","volume":"110","author":"WesierskaGadek","year":"1996","journal-title":"Gastroenterology"},{"key":"R30-31-20241201","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/227680a0","article-title":"Cleavage of structural proteins during the assembly of the head of bacteriophage T4.","volume":"227","author":"Laemmli","year":"1970","journal-title":"Nature"},{"key":"R31-31-20241201","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1172\/JCI114696","article-title":"The 210kD nuclear envelope polypeptide recognized by human autoantibodies in primary biliary cirrhosis is the major glycoprotein of the nuclear pore.","volume":"86","author":"Courvalin","year":"1990","journal-title":"J Clin Invest"},{"key":"R32-31-20241201","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF00351173","article-title":"Primary biliary cirrhosis sera recognize not only gp210 but also proteins of the p62 complex bearing Nacetylglucosamine residues from rat liver nuclear envelope. Antip62 complex antibody in PBC.","volume":"23","author":"Miyachi","year":"1996","journal-title":"Mol Biol Rep"},{"key":"R33-31-20241201","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/bmj.323.7321.1123","article-title":"Statistics notes: analysing controlled trials with baseline and follow up measurements.","volume":"323","author":"Vickers","year":"2001","journal-title":"BMJ"},{"key":"R34-31-20241201","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1055\/s-2005-916321","article-title":"Antinuclear antibodies in primary biliary cirrhosis.","volume":"25","author":"Invernizzi","year":"2005","journal-title":"Semin Liver Dis"},{"key":"R35-31-20241201","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1089-3261(03)00104-1","article-title":"Antimitochondrial and other autoantibodies.","volume":"7","author":"Bogdanos","year":"2003","journal-title":"Clin Liver Dis"},{"key":"R36-31-20241201","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1191\/0961203305lu2054oa","article-title":"Pathogenic autoantibodies in lupus nephritis.","volume":"14","author":"Waldman","year":"2005","journal-title":"Lupus"},{"key":"R37-31-20241201","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0022-510X(02)00200-9","article-title":"The role of antibodies in myasthenia gravis.","volume":"202","author":"De Baets","year":"2002","journal-title":"J Neurol Sci"},{"key":"R38-31-20241201","first-page":"269","article-title":"Autoimmunity in Addisons disease.","volume":"60","author":"Martin Martorell","year":"2002","journal-title":"Neth J Med"},{"key":"R39-31-20241201","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus.","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.21172","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200605000-00031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:02:54Z","timestamp":1733058174000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200605000-00031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.21172","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}